Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  -4.00 -3.76% 102.50 634,537 14:18:55
Bid Price Offer Price High Price Low Price Open Price
100.00 105.00 107.50 98.50 107.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.36 -4.52 -14.00 53
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:35 O 14,500 103.40 GBX

Genedrive (GDR) Latest News

More Genedrive News
Genedrive Takeover Rumours

Genedrive (GDR) Discussions and Chat

Genedrive Forums and Chat

Date Time Title Posts
08/7/202015:40Genedrive PLC (GDR) Covid19 Diagnostics497
03/7/202016:12Genedrive (GDR) One to Watch 884
02/7/202008:54Genedrive. A Game Changer for Global Covid 19 Testing Market?1,269
22/6/202020:45The New Genedrive Thread1
23/4/202016:50Still waiting....161

Add a New Thread

Genedrive (GDR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Genedrive trades in real-time

Genedrive (GDR) Top Chat Posts

Genedrive Daily Update: Genedrive Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 106.50p.
Genedrive Plc has a 4 week average price of 88p and a 12 week average price of 54p.
The 1 year high share price is 299p while the 1 year low share price is currently 6.50p.
There are currently 51,986,071 shares in issue and the average daily traded volume is 401,494 shares. The market capitalisation of Genedrive Plc is £53,285,722.78.
pal44: converted bond in to shares I dont get it why would anyone risk this on GDR perhaps there is chance that the share price will go much higher and yield some profit or the have cash to burn ..
daveweld: Saw a graph on one of bbs yesterday showing global infection rate daily total at its highest recorded so far, so testing is needed more than ever, best to deal in facts and facts are share price not currently moving much and market place is continuing to grow for testing company products, plus governments will look to stock pile testing equipment for foreseeable future, bit of a disconnect at moment with share price which I'm sure will be rectified once sales come in
daveweld: Rampers on this bb arnt influencing the share price up or down, institutional buyers or sellers are, with a highly inflated share price which may go 10 x higher, it's a news driven business at moment, look at ceo of omega and inadvertently influencing share price over there, while sales projections and orders are awaited for firm and sustained increase in value, days like today can have a big impact, frustrating, yes, but in the bigger picture, irrelevant, if product sales arrive big time, with a captive global market, value could go up dramatically, if the market for testing dissapears, price plummets, you should know the risks, personally I'm invested and believe in the products and company, ok ceo made a bit of a hash of it, long term, shouldn't make any difference when sales come in
viralspec: Patience, Bill. It's easy to find an obviously undervalued stock overdue a significant revaluation. It's a far greater ability to hold that stock while it increases and reaches a fair value, by ignoring the minute by minute or the daily price action. Don't forget: To match the current market cap at NCYT, the GDR share price would be £4.60. To match NCYT's market cap at it's peak, the GDR share price would be £7.80. To match the current market cap at AVCT, the GDR share price would be £10.00.
viralspec: The potential high here is far greater than that. To match the current market cap at NCYT, the GDR share price would be £4.60. To match NCYT's market cap at it's peak, the GDR share price would be £7.80. To match the current market cap at AVCT, the GDR share price would be £10.00.
aquilla: Well,I was talking about ODX earlier. Unfortunately for shareholders the company put out a statement 37 minutes before the close: "Omega (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, notes the recent rise in the Company's share price and confirms that it is not aware of any material reason for the significant increase. As previously announced the Company continues to work with its partner Mologic Ltd with regards its first generation ELISA antibody test for COVID-19 and also with the UK Rapid Test Consortium, which is jointly developing, and will manufacture, a Point-of-Care COVID-19 lateral flow antibody test. In respect of both these opportunities the Company will keep the market informed as matters develop. In a Sky News interview earlier today, the introduction referred to the Consortium being able to make 50m tests a year, a figure also referred to in a newspaper article published on 26 April 2020. This is not a figure that relates to the potential output from Omega and its manufacturing facilities alone." The share price went from 90p down to 60p, still up on the day but not quite as good as ODX holders had hoped! Let's hope GDR publicity, when it comes as come it must, is handled better!
daveweld: Avacta and Genedrives monumental increase in value has come from potential covid testing income, nothing else and there's no shame in that, having other great products is great but they have not driven this increase....With a captive marketplace of 8 billion customers, it doesn't matter how many other competitors come to the market place, both have great partnerships with cytiva, great products and sales soon to be realised ,In my opinion, the share price can only go one way... the question is how high can they go,With the massive upside being all other products in there range will be easily funded and propelled to market far quicker than otherwise would have happened, this then fuels even bigger increases in share price, a fire with unlimited fuel
daveweld: I am a complete amateur but the way I see it is....A good product soon to be ce approved..A market place that's desperate to open up and get back to work..Before the announcement share price rocketed up towards £3, People just got peed off at the timing and felt ripped off by the timing... never the less, as far as I see it, same principles apply...If share price was valued at £2.50- £3, then diluted by 20 plus % that equates to £2 ish,It's where it's at due to lack of trust and disappointment with what happened,I was fortunate enough to get guided by jev1 when I started trading, do your research, follow your gut instinct..My instinct said by at 78p when I did, it said buy at £2.20 on way down and buy broker option, why, good product nearly ready for market, has a good chance of success, same as avacta
bunz3: people might still trade this will not be surprised to see this share price dropping more as the days pass how many people might fear being caught with another placing at a low price again and when ever placing shares are sold not going to be good for share price
bunz3: pwhite have you looked at the big buys going into ncyt even though share price down so much £50k share buys also number of share buys around £30k to £36k interesting to watch their timing ,people would have noticed how last Wednesday big buys as share price was down then rns just before close also here good to see how holding don't let mms lower this is my hope ,hoping afternoon might see gdr share price tick up more
Genedrive share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200708 23:54:30